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Background
Selective internal radiation therapy (SIRT) with direct 90 Y-microspheres infusion into the hepatic artery is a novel, promising method for palliative treatment of primary and metastatic liver cancer [1, 2] The most important problem associated with this therapy is to calculate an adequate activity of 90 Y-microspheres, which can destroy liver tumors while sparing healthy liver tissue [3, 4] . The Y-microspheres distribution [3, 5] . In reality, there are two ways to calculate dosimetry after SIRT. The first one is the MIRD equation based on the assumption of uniform 90 Y distribution between the tumor and liver tissue compartments [6] . The second one is Monte Carlo simulation in which SPECT/CT images are used to obtain the isodoses curves and histograms of the target liver lesions [7] . For improvement of SIRT treatment results a detailed knowledge about 90 Y-microspheres distribution within the liver is required [3] . This way patients prone to potential radiation-induced liver disease (RILD) or patients with non-curative tumor dose may be selected immediately after a SIRT procedure. In www.nmr.viamedica.pl 
Materials and methods

Patient studies
Three patients (2 males, 1 female) were treated with 90 Y microspheres selective internal radioembolisation. All patients with unresectable liver metastases had adequate performance status and acceptable liver and renal function. Two patients had colorectal liver metastasis (mCRC) and one had metastasis from pancreatic cancer. A total of nine tumors was evaluated, 7 mCRC and 2 pancreatic cancer cases. The study was approved by Ethics Committee. All the patients were included in the study after signing a written informed consent.
Image evaluation
The patients were assessed before and after selective internal radioembolisation (SIRT) with computed tomography (CT). The whole liver volume, the liver tumors longest diameter and volume were collected. The Based on the data, the absorbed dose for the liver parenchyma and for each target liver tumor was calculated using the internal dosimetry schema of the Medical Internal Dose (MIRD) Committee of Society of Nuclear Medicine [6] . The absorbed dose was calculated using the T/N ratio in 99Tc-MAA, in 
SIRT procedure
The radioembolization procedure was conducted in line with guidelines approved by panel experts [3, 5] .
Candidates for radioembolization therapy were qualified by a multidisciplinary team consisting of interventional radiologists, oncologists, nuclear medicine specialists and surgeons in line with strict inclusion and exclusion criteria, which were published previously [3, 5] .
During the pre-treatment procedure, selective coil embolization of the gastroduodenal artery, right gastric artery and gallbladder artery were performed. The hepatopulmonary shunt, a potential gastrointestinal leak and the tumor to liver ratio were assessed after SPECT 
Results
All SIRT procedures were made with technical success. The whole dose prescribed for each patient was administered. There were no serious adverse events (SAE) observed. After the therapy, two patients had transient nausea, vomiting and mild pain in the liver region which required only symptomatic treatment. The details of clinical and treatment data are summarized in Table 1 .
A total of nine tumor target lesions were evaluated with imaging methods. Taking into consideration the response rate for each solid tumor, two CR, two PR and three SD were observed for seven mCRC at first follow-up. For two pancreatic lesions SD was found. Table 2 . Original
Discussion
In the recent years, there has been a growing interest observed in the use of 90 Y microspheres for regional liver tumor therapy. Promising treatment results such as improvements of time to progression, median overall survival and safety profile are an encouragement for further development of this method [1, [9] [10] [11] . Although we are aware that one of the main limitations of our study is a small group of patients, we can also confirm high efficiency of this therapy. We noticed one partial response and two stable diseases in our study. The time to progression ranged from 117 to 217 days in colorectal metastases and 214 days in pancreatic cancer metastases. There are no serious adverse events associated with the therapy. In our opinion, there is still room for improvement of results in this treatment. The first way is to treat patients as soon as possible. At present, results of prospective randomized multicenter trials are expected (i.e. SIRFLOX), in which radioembolisation in first line treatment is evaluated [12] . The second way is to improve knowledge on 90 Y-microspheres liver distribution, especially 90 Y liver dosimetry. The background for intra-arterial 90 Y-microspheres therapy is a special type of vascular anatomy of the liver. The majority of liver tumors' blood supply originates from the hepatic artery branches, then the portal vein (about 80-100% of their supply for tumors >3 mm) [13] . It is estimated that a dose higher than 70 Gy is required to destroy most of the liver tumors. High 90 Y-microspheres concentration within liver cancer leads to their destruction by way of ionizing radiation and embolization. The former has a crucial importance for the therapy [14] . The main limitation of radioembolisation is low liver tissue tolerance to radiation, with a possibility of serious adverse events after irradiation higher than 30 Gy [14, 15] . In our study, the radiation of the liver was estimated from 8.4 Gy to 25.8 Gy (mean 15.5 Gy) based on the MIRD formula and no serious side effects were reported (i. Tc-MAA because of a higher albumin diameter and intra-hepatic blood flow variations [3, 5, 16] . After the therapy, Tc-MAA injection immediately after a SIRT procedure [18] . However, in our opinion, embolic effects of resin microspheres may lead to inaccurate Y half-life is 2.67 days, the PET scan should be taken within this time limit in our opinion [3, 13, 21] . The time of a single PET imaging was 20 min in one case and 30 min in the next two patients. To obtain better image results we suggest taking a PET scan lasting 30 min for an administered dose ranging 1.2-2.2 GBq of 90 Y-microspheres. In order to protect the gantry detectors, we used a copper ring to absorb photons of low energy and we observed that 2 mm thickness of the ring is sufficient to achieve this aim. However, some authors do not use any protection and they have not noticed its saturation with total activity of 2.0 GBq. Yet, sometimes a higher dose may be needed for a patient's treatment and we suggest more caution in such cases [22] .
We noticed a similar T/N ratio calculated using [14, 15] . According to our study, tumor absorbed doses calculated with 90 Y-PET ranged from 144 Gy to 283 Gy, but when we consider tumor treatment results we can see mostly stable disease in overall response rate. Therefore, the absorbed doses calculated on the basis of the 99m Tc-MAA and bremsstrahlung SPECT/CT ratio ranging from 64 Gy to 183 Gy (except tumor Y-PET/CT imaging may be used not only to detect liver lesions after radioembolisation, but also to distinguish a necrosis area within solid tumors. Better resolution of this method may help to find out leaks of 90 Y microspheres to the digestive tract in our opinion [17, 20] . From our point of view, the possibility of estimation of radiation dose in liver lesions is very interesting. 
